CST, 48994S, KT-474

Product Usage Information
KT-474 is supplied as a lyophilized powder. For a 1 mM stock, reconstitute 1 mg of powder in 1.15 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
KT-474, also known as KYM-001, is a potent and selective degrader of interleukin-1 receptor-associated kinase 4 (IRAK4) (1). IRAK4 is a key protein involved in the interleukin-1 receptor (IL-1R)/toll-like receptor (TLR) signaling pathway (1-3). The IL-1R/TLR pathway is implicated in the pathogenesis of multiple inflammatory and autoimmune conditions, including hidradenitis suppurativa (HS), psoriasis, and atopic dermatitis (AD) (1,2). By targeting and degrading IRAK4, KT-474 effectively blocks the downstream inflammatory cascade triggered by the IL-1R/TLR pathway, reducing inflammation (1,2). In clinical trials, KT-474 reduced disease-relevant inflammatory biomarkers in the blood and skin samples of HS and AD patients and was associated with improvements in skin lesions (2,3).